Comparison Analysis of Total Cholesterol Level Examination Between Photometry and 3 Parameters Point of Care Testing Device by Nursidika, Perdina et al.
Medical Laboratory Technology Journal 
Copyright © 2018, MLTJ, ISSN 2461-0879 
Medical Laboratory Technology Journal  
 
Available online at : http://ejurnal-analiskesehatan.web.id 
4 (2), 2018, 49-57 
Comparison Analysis of Total Cholesterol Level Examination Between 
Photometry and 3 Parameters Point of Care Testing Device   
 
*Perdina Nursidika, Wikan Mahargyani, Fitri Kurnia Anggraeni  
  
Medical Laboratory Technology (D-4) , Jenderal Achmad Yani School of Health Sciences 
*Email : perdina.sidika@gmail.com  
DOI: 10.31964/mltj.v%vi%i.184  
 
Abstract:   Total cholesterol is the composition of many substances including cholesterol, tri-
glycerides, LDL cholesterol, and HDL cholesterol. Cholesterol examination is one of the most 
frequent tests required in the laboratory to monitor vascular and cardiovascular diseases. Most 
clinical pathology laboratories use photometer  to perform clinical chemistry checks. Cholester-
ol testing can also be done with Point of Care Testing (POCT) which has a working principle of 
biosensor technology. This research method is experimental, using 40 samples that can repre-
sent normal and pathological levels. All samples will be checked for total cholesterol with a 
photometer of CHOD-PAP method and 3 POCT Lipid Pro. The results showed linear regres-
sion y = 0.955x + 1.8325 with R2 of 0.9955. The linear regression value is calculated by Total 
Error (TE), while the Total Error Allowable (TEa) cholesterol is 10%. The bias value is 0.31%, 
TE for normal level = 5.92% and TE for high pathological level = 3.00%, it can be stated the re-
sult of examination can be compared or accepted. The% TE value obtained is less than the 
TEa value of cholesterol. It can be concluded that the total cholesterol results examined by the 
photometer and LipidPro are comparable. For further research it is advisable to use a total cho-
lesterol sample that has a value of more than 400 mg/dL.  
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INTRODUCTION 
        Cholesterol, triglycerides and lipoproteins 
are important component of the composition of 
fat fractions in the human body (Dwizella, et 
al., 2018). 
        Cholesterol is unsaturated alcohol with 
steroid compounds. Cholesterol is essential for 
the function of animal cells and the basic 
constituent of cell membranes. Cholesterol is a 
precursor to various important compounds 
such as bile salts, adrenal steroid hormones 
and gonads. (Apro, 2015; Miller, 2013). 
Triglycerides are esters of glycerol fatty acids 
and it represent the main lipid components of 
fat from food and animal fat deposits 
(Tsoupras, et al., 2018).  
Cholesterol and triglycerides are insoluble 
non-polar compounds transported by plasma 
lipoproteins (Welty, 2013). Plasma lipoproteins 
are divided according to density, 
electrophoretic mobility, size, and content of 
cholesterol, triglycerides, and proteins (Pan & 
Segrest, 2016). Lipoproteins are divided into 
five main classes, chylomicrons, very low 
density lipoproteins (VLDL), intermediate-
density lipoproteins (IDL), low-density 
lipoproteins (LDL), and high-density 
lipoproteins (HDL) (Sacks & Brewer, 2014). 
Preliminary studies of cholesterol are a 
key component of arterial plaque which raises 
the cholesterol hypothesis in the pathogenesis 
of atherosclerosis (Buja, 2014; Steinberg, 
2013). Population studies have shown that 
elevated LDL cholesterol levels (Zmysłowski & 
Szterk, 2017) and apolipoprotein B (apoB) 
100, The main structural protein LDL, is 
directly related to the risk of atherosclerotic 
cardiovascular events (ASCVE) (Ference et 
al., 2017). High triglyceride levels in the blood 
are one of the causes of atherosclerosis 
(Peng, Luo 2017). LDL peroxidation is the 
main key in the initiation and progression of 
atherosclerosis (Matsuura et al., 2014). Ather-
osclerosis is a systemic disease (Hoshino et 
al., 2018). About 60% of patients with periph-
eral artery disease will have ischemic heart 
disease, and 30% have cerebrovascular dis-
ease.  
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Within five years of diagnosis, 10-15% pa-
tients with intermittent claudication will die 
caused by cardiovascular disease. Therefore, 
treatment begins with identification and modifi-
cation of common risk factors for peripheral 
artery disease, heart disease, and stroke 
(Frostegård, 2013; Morley et al., 2018).  
Cholesterol examination is the most 
frequently requested tests in the laboratory to 
monitor vascular disease which includes 
coronary heart disease, cerebral vascular 
disease, and peripheral blood vessels 
(Sniderman et al., 2016). Most clinical patholo-
gy laboratories use photometer devices to con-
duct clinical chemistry examinations. This tool 
can determine the level of an ingredient in 
body fluids such as serum or plasma. 
Photometer is a standard method of clinical 
chemistry examination but has several 
disadvantages, such as expensive prices, 
invasive blood sampling and relatively longer 
examination times (Frostegård, 2013; Morley 
et al., 2018). The length of the examination 
can cause prolonged results and a delay in di-
agnosis. This will lead to services that are not 
suitable even fatal consequences can occur 
death. Continuously developed inspection 
technology is made to measure the inspection 
process, namely the Point of Care Testing 
(POCT) (Kost et al., 1999). Some countries 
like China have used POCT to reduce the 
number of people with dyslipidemia (Zhang et 
al., 2015).  
Point of Care Testing (POCT) is a digital 
tool that uses cell measurements where cer-
tain reactions can take place. This cell can be 
a porous matrix, chamber or surface. Measur-
ing devices can be visual, optical or monitoring 
electrochemical reactions that occur. Generally 
POCT mechanism use biosensor technology. 
Biosensor technology generated the electrical 
charge by chemical interactions between cer-
tain substances in blood and chemicals in dry 
reagents (strips) and will be measured then 
converted into numbers that correspond to the 
amount of electric charge. The resulting num-
ber is considered equal to the level of sub-
stance measured in blood. The advantage of 
the POCT is that the results are fast so that 
the diagnosis can be immediately enforced 
and the action / treatment can be given imme-
diately. In addition, this tool is easy to use, the 
sample volume used is less, the device is 
smaller so it does not need a special room and 
can be carried or mobile. The disadvantage of 
this tool is that precision and accuracy are not 
good if compared to the reference method. In 
addition measurement capability is limited be-
cause it is mediated by temperature, humidity, 
and hematocrit value (Kemenkes, 2010). 
      The use of POCT only takes less than 2 
minutes to perform cholesterol and triglyceride 
tests (Xavier et al., 2016). This makes POCT 
suitable for disease screening tests (Ferreira 
et al., 2015). POCT can be used as a 
screening filter and diagnosis of 
hypercholesterolemia (Peverelle et al., 2018), 
and CVD risk assessment (OAM, 2016), and 
long-term monitoring of patients who have un-
dergone treatment (Plüddemann et al., 2012).          
       POCT tools can be used by someone who 
does not have the basis of laboratory 
knowledge, they do not understand quality 
control over the results of POCT examination. 
Based on Food and Drug Administration (FDA) 
data from the United States between 1984 and 
1992, there were 24 deaths and 984 morbidity 
due to POCT use because of inappropriate 
testing. Errors in dealing with patients are usu-
ally 50% due to incorrect instructions 
(indications), 32% fail to act because they are 
not in accordance with the test results (Kost et 
al., 1999).  
POCT that is often used in hospital and 
clinic laboratories is LipidPro. The advantage 
of using this tool is faster inspection time and 
can reduce medical waste because 1 strip can 
directly check 3 parameters. Lipid Pro is a tool 
to check blood lipid levels in vitro which helps 
with practical and easy measurement of total 
cholesterol, HDL (High Density Lipoprotein), 
LDL (Low Density Lipoprotein), and triglycer-
ides. The principle of this tool is to read the re-
flection of light based on changes in the color 
of the results of the enzymatic reaction be-
tween the substrate (total cholesterol, HDL 
cholesterol and triglycerides) and the enzymes 
in the strip. When the sample is dropped on 
the test strip, the sample will react and pro-
duce the color that will be read by the tool. The 
intensity of the measured color is proportional 
to its concentration. The instrument compo-
nent changes the resulting color to a numerical 
value and displays the value on the screen 
(Osang Healthcare, 2017). 
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MATERIAL AND METHOD 
This research method is experimental. 
The sample of the study was 40 patients who 
were examined for cholesterol levels in the 
Hospital in Bandung in the period February-
March 2018. This research is approved by 
Jenderal Achmad Yani School of Sciences 
ethical committee declared by the ethical 
clearance number 013/KEPK/VIII/2018. 
Before the examination, the patient had 
to fast beforehand to avoid the influence of the 
examination from the food. Specimens used 
are serum that is not hemolysis. The number 
of samples is 40 serum in accordance with 
Westgard provisions for comparability testing. 
Cholesterol level examination using 
ELITech Selectra Pro-M and POCT Lipid Pro 
Photometers. The photometer used is capable 
of checking 266 tests / hour, can detect bar-
codes, with a Quartz-Iodine light source 12V-
20W, absorbance photometric range of -0.1 to 
3. ELITech Selectra Pro-M photometers using 
reagents have specifications can check cho-
lesterol by range cholesterol levels of 20-600 
mg / dL, measurements with the end point 
method, and 505nm wavelength. Cholesterol 
testing with POCT Lipidpro with the specifica-
tions of one tool can check total cholesterol, 
triglycerides, and HDL-cholesterol, measure-
ment time of 2 minutes, and have 200 data 
memory. LipidPro uses a kit with 5 unit choles-
terol esterase enzyme specifications, 3.3 units 
of cholesterol oxidase, 3.3 units of peroxidase, 
4-9 μg of Aminoanthipirin, and 81 μg of aniline 
derivate.  
The material used in this study was 
normal control serum (CTN17L04 LOT) and 
pathological (No 01-1030 LOT), patient serum, 
Elitech Group cholesterol reagent, POCT 
LipidPro total cholesterol strip and tools. 
Cholesterol examination with an ELItech 
Selectra Pro-M photometer performed an 
internal calibration before conducting the 
examination, followed by inserting 0.5-50 μL of 
serum into the cuvette, choosing a cholesterol 
check then clicking start (Elitech Group, 2018). 
Cholesterol examination with LipidPro by in-
serting the strip into the tool, entering the strip 
code on the tool, using the lancing device to 
take a blood sample and drop the sample on 
the strip. The results will be read after two 
minutes (Osang Healthcare, 2017).  
The examination begins with internal 
quality stabilization with serum control checks. 
After the data is on the target value and range 
of examination, then it is followed by samples 
check. For normal control serum, the target 
value is 131 mg/dL with a range of 105-157 
mg / dL. Pathological control series, the target 
value is 221 mg / dL with a range of 177-265 
mg / dL. Data obtained from measurements of 
samples in the form of absorbance values for 
both Photometers and Lipids Pro. Data analy-
sis technique uses linearity regression test cal-
culation. Linear regression equation from Y to 
X is formulated shown by equation 1; 
 
 
 
 
 
 
 
 
Description:  
Y = dependent variable 
X = independent variable 
a = intercept 
b = regression coefficient / slope  
 Then the bias calculation is performed. 
Bias is the difference between the results of 
the serum control level and the actual value. 
The bias value is processed into the total error 
value and the allowable (Tea) cholesterol total 
error value. Cholesterol TEa is 10% 
(Westgard, 1992). Tea eaquation shown by 
equation 2; 
 
 
 
 
 
 
 
RESULT AND DISCUSSION 
 This research was conducted in one 
hospital in the Bandung with the parameter to-
tal cholesterol levels. The number of samples 
used were 40 samples and were examined for 
7 days, it measured by using POCT and Pho-
tometer. Before measuring the patient sample, 
quality control (QC) performed by observing 
control serum during the examination period. 
The results of the control serum examination 
show that a sample check can be performed. 
The results of the examination of the normal 
control serum on the photometer are in table 1.  
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Based on the measurement data of con-
trol values that performed everyday, the data 
is accepted because it is in the value range of 
the control material of photometer. After being 
calculated, it was obtained the value of SD = 
1.78, CV = 1.89% and the value of TEa 10%. 
SD & CV values obtained <½ TEa so that the 
QC results are acceptable. Based on the re-
sults of this QC, the photometer can be used 
as a reference in measuring cholesterol levels. 
Furthermore, also performed control 
quality for POCT. The monitoring was carried 
out using normal and high pathological control 
serum. POCT control material test results can 
be seen in table 2. The POCT is used to com-
pare, therefore the impression test is done 
first. The control material was examined for 5 
consecutive days and carried out in duplicate. 
This impression test aims to estimate random 
errors in a method and also the initial step in 
determining the method validation (Biswas et 
al., 2015). POCT control serum measurement 
results for normal levels found SD = 1.43 mg / 
dl, CV = 1.8% while high pathological values 
obtained SD = 1.39 mg / dl, CV = 0.7%, and 
TEa at this examination is 10%. After the cal-
culation is obtained SD and CV values <½ TEa 
value, then the tool has a good impression, so 
it can be used to compare and measure sam-
ples. 
From the results of the control serum 
measurements carried out for 5 days showing 
the value of the control received either using a 
Photometer or POCT, the test can be done us-
ing a photometer and also POCT. The results 
of measurements and linear regression calcu-
lations can be seen in table 3.  
Table 3 shows the average results 
obtained from photometer is 205.1 mg/dL while 
the average obtained from POCT is 206 mg/
dL. Slope value (b) = 0.9955x, while intercept 
value (a) = 1.83 and linear regression value 
(R²) = 0.9915. After obtaining a linear 
regression value calculated TE (Total Error), 
while the total allowable error value (TEa) 
cholesterol is 10% (Westgard, 1992). The re-
sults obtained bias value is 0.31%, TE for the 
normal level is 5.92% and TE for the high 
pathological level is 3.00%. It can be stated 
that the results of the examination can be com-
pared or accepted. The data is plotted into the 
graph to find out the equation of the line and 
the regression value can be seen in figure 1  
Figure 1 shows the linearity of sample 
absorption measured using a photometer com-
pared to POCT obtained R2 = 0.995. Then the 
correlation and regression tests were carried 
out. The results of the correlation and regres-
sion test can be seen in table 4.  
The R2 value is 0.995 then proceed 
with calculating linear regression, and the test 
used was T Pearson. T test showed p-value is 
0.000, it can be stated that there is a correla-
tion between the result performed by photome-
ter and POCT. For more details, correlation 
and regression test is conducted. Correlation 
test results obtained 0.995,  the results is more 
than 0.99 then the T test used is T person.  
Table 1 Quality control result for Photometer 
Description Average 
mg/dL 
SD 
mg/dL 
CV 
% 
Target range 
mg/dL 
Intepretation 
Normal control 108,75 1,78 1,89 105-157 Accepted 
            
Table 2 Quality control result for POCT  
Description Average 
mg/dL 
SD 
mg/dL 
CV 
% 
Target range 
mg/dL 
Intepretation 
Normal control 126,4 1,43 1,13 105-157 Accepted 
Pathological control 206,8 1,39 0,7 177-265 Accepted 
Description: 
SD  = Standard deviation 
CV = Coefficient of Variation  
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No. POCT 
mg/dL 
Photometer 
 mg/dL 
y-x 
1. 127 125 2 
2. 130 127 3 
3. 136 133 3 
4. 141 145 -4 
5. 160 155 5 
  6. 167 160 7 
  7. 170 166 4 
  8. 170 168 2 
  9. 173 174 -1 
  10. 173 177 -4 
  11. 180 179 1 
  12. 184 180 4 
  13. 180 181 -1 
  14. 179 184 -5 
  15. 192 188 4 
  16. 192 189 3 
  17. 188 190 -2 
  18 191 194 -3 
  19. 193 198 -5 
  20. 193 199 -6 
  21. 207 203 4 
  22. 224 221 3 
  23. 233 230 3 
  24. 221 225 -4 
  24. 230 233 -3 
  26. 211 206 5 
  27. 258 251 7 
  28. 230 226 4 
  29 251 246 5 
30 218 221 -3 
31. 227 224 3 
32. 235 230 5 
33. 224 219 5 
34. 201 204 -3 
35. 273 269 4 
36. 278 275 3 
37. 266 269 -3 
38. 265 270 -5 
39. 276 281 -5 
40. 293 289 4 
 ̅ 206 mg/dl 205,1 mg/dl   
Table 3 Cholesterol total result 
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The T person test is obtained p-value 
0.000, which means the value less than 0.005, 
it can be stated Ha: there is correlation. In this 
correlation test has a limit of 0-1.0, in this test 
the correlation value obtained is 0.995, so it 
shows a very strong correlation because the 
value is close to 1.0. 
In this study, all  subjects had total cho-
lesterol levels in accordance with the limit of 
ability (range) of detection devices that is 100-
400 mg/dL. This is related to the cut-off value 
of the tool and also the limited number of en-
zymes contained in the test strip. The mini-
mum value on the measurement results ob-
tained is 127 mg / dl and the maximum value 
is 293 mg / dl, then the sample results ob-
tained into the range also represent normal 
and pathological values. Thus it can be stated 
that there is correlation between the POCT 
and the Photometer, but only at this limit. For a 
value of 300-400 it still needs to be tested fur-
thermore. The availability of POCT for monitor-
ing lipid levels has increased in recent years 
(Abel, 2015). Each POCT must be validated 
for biases and inaccuracies to ensure that 
appropriate screening decisions and disease 
tests are carried out (Park et al., 2016). 
Bias (inaccuracy) is defined as the 
difference between laboratory results and 
standards. The National Cholesterol Education 
Program (NCEP) in the United States 
recommends a bias value of 3% for cholesterol 
and 5% for triglycerides (McPherson & Pincus, 
2017). In this study, the bias value is not more 
than 3%, which is 0.31%. Impression refers to 
the reproducibility of test results. Impression 
allowed is 3% for cholesterol and 5% for 
triglycerides (McPherson & Pincus, 2017)  
Overall, the analytical results of POCT 
must be the same as the equipment used in 
the laboratory such as a photometer, so as to 
ensure that POCT does not endanger patient 
examination standards and clinical decision 
making. In addition, knowledge is needed 
especially for lay users, that POCT is different 
from laboratory settings (Onovughakpo-Sakpa 
et al., 2015).  
Fig. 1.  Graphic Photometer and POCT comparison test 
Table 4 Correlation and Regression for Total Cholesterol Examination using POCT 
with Photometer  
   ̅ SD r t p-value 
POCT 208,02 42,48 0,995 66,593 0,000 
Fotometer 207,15 42,86       
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CONCLUSSION 
The results of examination of total 
cholesterol levels using a photometer and 
POCT showed results that were almost the 
same as the tolerance limit or TE <Tea and a 
bias (inaccuracy) of 0.31%. It can be 
concluded that total cholesterol results using 
comparable photometer and POCT Lipid Pro. 
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